Biologics and newer medicines

Everything here about biologic and small-molecule medicines such as infliximab, adalimumab and others: our articles first, then short answers, the words you may hear, and the original sources.

Articles

Common questions 13

What is 'top-down' treatment and is it better?

Top-down means starting strong treatment, such as a biologic plus an immunosuppressant, soon after diagnosis instead of trying milder medicines first ('step-up'). In the UK PROFILE trial of newly diagnosed adults, 79% on top-down treatment stayed in remission without steroids or surgery for a year, compared with 15% on step-up, with fewer flares and operations. Your team will weigh this up for your own situation.

Source

Why might I be given azathioprine alongside infliximab?

The SONIC trial found that people who had not had these drugs before did better on infliximab plus azathioprine together than on either alone: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone. The European and UK guidelines draw on trials like this. Your team will discuss the extra monitoring and side effects of using two medicines.

Sources

Which biologic is best for Crohn's?

There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.

Sources

Is surgery ever a better choice than a biologic?

Sometimes. The LIR!C trial compared keyhole surgery to remove a short diseased section at the end of the small bowel with infliximab, in people for whom standard medicines had not worked. The researchers concluded surgery is a reasonable alternative for this group, and longer follow-up supported this. It depends on where and how extensive your Crohn's is, so it is a discussion to have with your IBD team and surgeon.

Sources

What is the difference between 'step-up' and 'top-down' treatment?

Step-up means starting with simpler treatments such as steroids and only moving on to stronger medicines if those do not work. Top-down means starting a biologic early, usually infliximab together with an immunomodulator. The UK PROFILE trial found that, in newly diagnosed people with active Crohn's, top-down treatment led to far more steroid-free and surgery-free remission after a year, and fewer hospital stays and complications after five years. The 2025 BSG guideline now suggests early infliximab for moderate to severe Crohn's.

Sources

What is a biologic medicine?

Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.

Sources

What is a biosimilar, and is it as good as the original brand?

A biosimilar is a version of a biologic medicine shown to have no meaningful differences in quality, safety or effectiveness from the original brand. For example, Remicade was the first infliximab and Remsima, Inflectra, Flixabi and Zessly are biosimilars; Humira was the first adalimumab and Amgevita, Hyrimoz, Imraldi, Idacio and Yuflyma are biosimilars. NHS England says switching between them is now accepted practice. A Cochrane review found infliximab and its CT-P13 biosimilar may work similarly.

Sources

Why has my hospital switched my biologic to a different brand?

NHS England encourages hospitals to use biosimilars because they work as well as the original brand and cost less, and the savings help pay for other treatments. Crohn's & Colitis UK notes you may be moved between brands and there may be small differences, such as how the injection pen works. If you have concerns, ask your IBD team for support with the new device.

Sources

Which biologics and targeted medicines are approved for Crohn's on the NHS?

NICE has approved infliximab and adalimumab (TA187), vedolizumab (TA352), ustekinumab (TA456), risankizumab (TA888), upadacitinib (TA905), mirikizumab (TA1080) and guselkumab (TA1095) for Crohn's, each under certain conditions. Most of the newer ones are for people whose disease has not responded to, or cannot have, an earlier treatment. Your IBD team decides with you which is suitable.

Sources

Why does my team check drug levels and antibodies on infliximab or adalimumab?

Some people's bodies make antibodies against infliximab or adalimumab, which can stop the medicine working. Crohn's & Colitis UK says your team may check the level of medicine and antibodies in your blood. The 2025 BSG guideline says these tests can help decide whether to adjust treatment or switch to a different medicine, and NHS Lothian describes checking levels after starting and then at least yearly. Taking an immunomodulator alongside can lower the chance of antibodies.

Sources

Why might I take azathioprine or methotrexate alongside a biologic?

The 2025 BSG guideline recommends starting infliximab or adalimumab together with a thiopurine to reduce the chance of the body making antibodies against the biologic. Cochrane reviews found infliximab plus azathioprine or mercaptopurine probably works better than a thiopurine alone. Crohn's & Colitis UK also explains that methotrexate can reduce these antibodies.

Sources

Is vedolizumab still used for Crohn's?

NICE still recommends vedolizumab (Entyvio) after an anti-TNF has failed or is unsuitable, and a Cochrane review found it works better than placebo. However, the 2025 BSG guideline no longer routinely suggests it for moderate to severe Crohn's, because the effect seen in trials was small. The review of the guideline says it may still suit selected people, after discussion with the IBD team.

Sources

Can I stop my biologic once my Crohn's is in remission?

The 2025 BSG guideline does not suggest routinely stopping advanced therapy, because about a third of people relapse within one to two years of stopping, even after the gut has healed. It says any decision should be made jointly with your IBD team, with close monitoring afterwards. NICE appraisals also ask for regular reviews of whether ongoing treatment is still needed. Never stop a medicine without speaking to your team.

Sources

Words you might hear 21

Adalimumab
An anti-TNF biologic you inject under your skin at home with a pen or syringe.
Advanced therapy
A general term for biologics and newer targeted medicines such as JAK inhibitors.
Anti-drug antibodies
Antibodies your immune system can make against a biologic, which may stop it working.
Anti-tnf
A group of biologic medicines that block TNF, a chemical messenger that drives inflammation. Includes infliximab and adalimumab.
Biologic-naive
Describes someone who has never had a biologic medicine before. Trials often report results separately for these people because first biologics tend to work better.
Biologics
Medicines made from living cells that target specific parts of the immune system to control Crohn's, usually given by injection or drip.
Biosimilar
A near-identical, cheaper version of a biologic medicine made after the original's patent ends. It has been shown to work the same way.
Combination therapy
Taking two types of treatment together, usually a biologic such as infliximab plus an immunosuppressant such as azathioprine.
Guselkumab
A biologic that blocks the inflammatory protein IL-23.
Immunogenicity
The tendency of a medicine to trigger the immune system into making antibodies against it.
Infliximab
An anti-TNF biologic given by drip in hospital or as an injection under the skin.
Infusion
A medicine given slowly through a drip into a vein, usually in hospital.
Interleukin inhibitor
A medicine that blocks interleukins, proteins the immune system uses to send inflammation signals.
Loss of response
When a medicine that was working stops controlling Crohn's.
Mirikizumab
A biologic that blocks the inflammatory protein IL-23.
Risankizumab
A biologic that blocks the inflammatory protein IL-23. Started by drip, then injected under the skin.
Subcutaneous injection
An injection into the fatty layer just under the skin, often given at home with a pen.
Therapeutic drug monitoring
Blood tests that measure how much of a medicine (such as infliximab or adalimumab) is in your blood, and whether your body has made antibodies against it, so the dose can be adjusted.
Top-down treatment
Starting strong treatment such as a biologic, often with an immunosuppressant, soon after diagnosis, instead of trying milder medicines first.
Ustekinumab
A biologic that blocks the inflammatory proteins IL-12 and IL-23. Started by drip, then injected under the skin.
Vedolizumab
A biologic that stops certain immune cells moving into the gut wall. Given by drip or injection.

Further reading 52

The original NHS, NICE, charity and research pages on this topic, with our summary of each.

Guides for patients and families

Web pages 3

Biosimilar medicines

NHS England Web page Patients and professionals

NHS England's page on biosimilars: biological medicines shown to have no meaningful differences in quality, safety or effectiveness from the original brand. It explains why the NHS encourages their use, that switching between the original and a biosimilar is now accepted practice, and how savings are reinvested.

Topics Biologics and newer medicines Medicines

Jargon explained biosimilar originator medicine switching

Leaflets 1

Starting biologic medication

Royal Free London NHS Foundation Trust Leaflet Aug 2025 For patients

A patient leaflet for people starting a biologic for IBD. It explains what biologics are, when they are used (often after steroids or azathioprine have not worked), and lists the biologics used at the hospital, their brands and how each is given.

Topics Biologics and newer medicines

Jargon explained biologic infusion biosimilar

Guides 12

Guselkumab

Crohn's & Colitis UK Guide Dec 2025 For patients

A guide to guselkumab (Tremfya), an IL-23 blocking medicine. The first three doses can be a drip or an injection, after which it is injected under the skin; the page covers vaccines and side effects.

Topics Biologics and newer medicines

Jargon explained IL-23 interleukin inhibitor

Infliximab

Crohn's & Colitis UK Guide Jun 2024 For patients

A guide to infliximab, an anti-TNF biologic given by drip or as an injection under the skin. It lists the original brand Remicade and biosimilars such as Remsima, Inflectra, Flixabi and Zessly, and explains checks before starting, that your team may measure drug and antibody levels in your blood, and possible side effects.

Topics Biologics and newer medicines Monitoring

Jargon explained anti-TNF infusion subcutaneous biosimilar drug levels antibodies

Risankizumab

Crohn's & Colitis UK Guide Jul 2023 For patients

A guide to risankizumab (Skyrizi), a biologic that blocks the IL-23 protein involved in inflammation. You start with a few drips, then have regular injections under the skin; the page explains trial results and side effects.

Topics Biologics and newer medicines

Jargon explained IL-23 interleukin biologic

Biologic medicines and other targeted treatments

Crohn's & Colitis UK Guide Jul 2023 For patients

An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.

Topics Biologics and newer medicines Medicines

Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy

Fistulas

Crohn's & Colitis UK Guide Jan 2026 For patients

Explains why fistulas are more common in Crohn's, the different types (perianal is the most common), how they are found, including examination under anaesthetic and MRI, and treatment with medicines, setons and other surgery. It describes what living with a seton is like and gives clear urgent-help advice: contact your GP or 111 for fever, pain and pus, and 999 or A&E for possible sepsis.

Topics Around the bottom (perianal) Complications Surgery Urgent help Biologics and newer medicines

Jargon explained fistula perianal fistula seton examination under anaesthetic perianal abscess sepsis fistulotomy anti-tnf perianal metronidazole ciprofloxacin

Immunosuppressant precautions

Crohn's & Colitis UK Guide Oct 2023 For patients

Practical ways to lower the risks of medicines that suppress the immune system. You should not have live vaccines while on an immunosuppressant, but non-live vaccines such as the injected flu jab, COVID-19, Shingrix shingles and pneumococcal vaccines are safe. It explains checks for chickenpox immunity, the slightly raised risk of some cancers, especially skin cancer, and sun safety, plus food hygiene and travel precautions.

Topics Immunosuppressants Vaccinations and infections Cancer risk and screening Travel Biologics and newer medicines

Jargon explained immunosuppressant live vaccine non-live vaccine Shingrix pneumococcal vaccine JAK inhibitor anti-TNF

Systematic reviews 6

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis

Cochrane Systematic review Jun 2026 Patients and professionals

An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.

Topics Biologics and newer medicines Research

Jargon explained network meta-analysis relative risk number needed to treat biosimilar

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Cochrane Systematic review May 2025 Patients and professionals

Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.

Topics Biologics and newer medicines

Jargon explained IL-12/23 induction certainty of evidence

Vedolizumab for induction and maintenance of remission in Crohn's disease

Cochrane Systematic review Jul 2023 Patients and professionals

Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.

Topics Biologics and newer medicines Research

Jargon explained high-certainty evidence induction maintenance integrin

Studys 14

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE)

New England Journal of Medicine Study Jul 2024 Patients and professionals

A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.

Topics Biologics and newer medicines Research

Jargon explained non-inferiority endoscopic remission anti-TNF

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)

The Lancet Gastroenterology & Hepatology Study May 2024 Patients and professionals

A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.

Topics Biologics and newer medicines Research About Crohn's disease

Jargon explained top-down treatment step-up treatment biomarker steroid-free remission top-down step-up immunomodulator randomised controlled trial

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE)

The Lancet Study Jun 2022 Patients and professionals

One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.

Topics Biologics and newer medicines Research

Jargon explained head-to-head trial biologic-naive confidence interval

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

The Lancet Study May 2022 Patients and professionals

Two trials testing risankizumab (Skyrizi) drips to bring active Crohn's under control, including in people for whom other biologics had failed. Risankizumab led to more remissions, and more improvement seen on camera tests of the bowel, at 12 weeks than placebo, and was generally well tolerated.

Topics Biologics and newer medicines

Jargon explained induction phase 3 trial endoscopic response

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease (UNITI)

New England Journal of Medicine Study Nov 2016 Patients and professionals

The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.

Topics Biologics and newer medicines

Jargon explained induction maintenance IL-12/23 placebo

Vedolizumab as induction and maintenance therapy for Crohn's disease (GEMINI 2)

New England Journal of Medicine Study Aug 2013 Patients and professionals

The main trial of vedolizumab (Entyvio) in Crohn's. It helped more people reach remission than placebo by week 6, and people who responded and stayed on it were more likely to be in remission at one year. Side effects, including infections, were somewhat more common than on placebo in this trial.

Topics Biologics and newer medicines

Jargon explained integrin induction maintenance serious adverse event

Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC)

New England Journal of Medicine Study Apr 2010 Patients and professionals

A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.

Topics Biologics and newer medicines Immunosuppressants Research

Jargon explained combination therapy steroid-free remission mucosal healing randomised controlled trial

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

Gastroenterology Study Jan 2007 Patients and professionals

The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.

Topics Biologics and newer medicines

Jargon explained maintenance remission CDAI placebo

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

The Lancet Study May 2002 Patients and professionals

This trial asked whether people who improve after a first dose of infliximab should keep having it. Those given regular doses every 8 weeks were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those who stopped. Serious infections were no more common. It set the pattern of regular, ongoing infliximab treatment.

Topics Biologics and newer medicines Research

Jargon explained maintenance therapy remission placebo

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial

The Lancet Gastroenterology & Hepatology Study Oct 2020 Patients and professionals

A longer look back at the people in the LIR!C trial. It supported keyhole removal of the end of the small bowel as a real option for people with short, mainly inflamed (not narrowed) disease when standard medicines have not worked. In both groups, adding an immunosuppressant was linked to the benefit lasting longer.

Topics Surgery Biologics and newer medicines

Jargon explained retrospective hazard ratio immunomodulator

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

The Lancet Study Dec 2017 Patients and professionals

CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.

Topics Monitoring Biologics and newer medicines Research

Jargon explained tight control faecal calprotectin CRP mucosal healing treat to target

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease (LIR!C)

The Lancet Gastroenterology & Hepatology Study Nov 2017 Patients and professionals

A Dutch and UK trial in adults whose Crohn's affected a short stretch (under 40 cm) at the end of the small bowel and had not settled with standard medicines. Keyhole surgery to remove that section was compared with infliximab, looking mainly at quality of life at one year. The authors concluded surgery is a reasonable alternative to infliximab for this group. Over about four years, 37% of the infliximab group ended up having surgery anyway.

Topics Surgery Biologics and newer medicines Research

Jargon explained laparoscopic ileocaecal resection terminal ileum quality of life terminal ileitis

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children (REACH)

Gastroenterology Study Mar 2007 Patients and professionals

The key trial of infliximab in 112 children with moderate to severe Crohn's. After the first three doses, 88% had improved and 59% were in remission. Children given the drug every 8 weeks afterwards did better at one year than those given it every 12 weeks. It led to infliximab being used for children.

Topics Children and young people Biologics and newer medicines

Jargon explained induction maintenance clinical response PCDAI

Infliximab maintenance therapy for fistulizing Crohn's disease (ACCENT II)

New England Journal of Medicine Study Feb 2004 Patients and professionals

A trial in people with Crohn's fistulas (abnormal tunnels, often around the anus) who had responded to infliximab. Carrying on with infliximab every 8 weeks kept people well for much longer than switching to a dummy drug. At one year, 36% on infliximab had no draining fistulas, against 19% on placebo.

Topics Around the bottom (perianal) Biologics and newer medicines

Jargon explained fistula fistulizing disease placebo

For health professionals

Guidelines 13

Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)

NICE Guideline Aug 2025 For professionals

NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.

Topics Biologics and newer medicines Medicines

Jargon explained IL-23 inhibitor TNF-alpha inhibitor conventional treatment

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

NICE Guideline Jul 2017 For professionals

NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.

Topics Biologics and newer medicines Medicines

Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

NICE Guideline Aug 2015 For professionals

NICE's appraisal recommending vedolizumab (Entyvio) for adults with moderate to severe Crohn's disease when an anti-TNF medicine has failed, stopped working or is unsuitable. It is given as a planned course and reassessed at 12 months.

Topics Biologics and newer medicines Medicines

Jargon explained anti-TNF TNF-alpha inhibitor patient access scheme moderately to severely active

Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

NICE Guideline May 2010 For professionals

NICE's appraisal approving infliximab and adalimumab on the NHS for adults with severe active Crohn's disease when standard treatments such as steroids or immunosuppressants have not worked or cannot be used. It applies to biosimilar versions too, and says treatment should be reviewed at least every 12 months to decide whether to continue.

Topics Biologics and newer medicines Medicines

Jargon explained anti-TNF biosimilar conventional therapy severe active Crohn's disease

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

European Crohn's and Colitis Organisation (J Crohns Colitis) Guideline Oct 2024 For professionals

Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.

Topics Medicines Biologics and newer medicines Immunosuppressants Around the bottom (perianal)

Jargon explained biologic immunomodulator induction maintenance de-escalation perianal fistula GRADE

AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

American Gastroenterological Association (Gastroenterology) Guideline Jun 2021 For professionals

The American Gastroenterological Association's guideline on medicines for moderate to severe Crohn's, including fistulas around the anus. It rates the strength of evidence behind each drug option. It is American, so some drug choices and approvals differ from the NHS, but it is free to read in full and widely cited.

Topics Medicines Biologics and newer medicines Around the bottom (perianal)

Jargon explained luminal perianal fistulizing certainty of evidence

Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (HTG401, formerly DG22)

NICE Guideline Feb 2016 For professionals

NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.

Topics Monitoring Biologics and newer medicines

Jargon explained therapeutic drug monitoring drug level anti-drug antibodies ELISA anti-TNF

Management of pediatric Crohn's disease: an ECCO-ESPGHAN guideline update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Aug 2026 For professionals

The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.

Topics Children and young people Diet and nutrition Biologics and newer medicines Monitoring

Jargon explained anti-TNF therapeutic drug monitoring exclusive enteral nutrition endoscopic remission

A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease

Gut Guideline Sep 2014 For professionals

An international expert consensus on perianal fistulas in Crohn's. Key points: combine more than one test for an accurate picture, always drain infection before starting immune-suppressing treatment, anti-TNF medicines are the main treatment, and definitive surgical repair is only considered when the rectum is not inflamed.

Topics Around the bottom (perianal) Surgery Biologics and newer medicines

Jargon explained perianal fistula anti-tnf proctitis seton

The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Feb 2021 For professionals

European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.

Topics Children and young people Medicines Diet and nutrition Biologics and newer medicines

Jargon explained paediatric penetrating disease stricturing disease exclusive enteral nutrition anti-TNF immunomodulator therapeutic drug monitoring

Studys 2

Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial

The Lancet Gastroenterology & Hepatology Study Nov 2026 For professionals

Five-year follow-up of the PROFILE trial. People who had early top-down treatment were less likely to be admitted to hospital or to develop strictures or fistulas than those treated step-up, with no difference seen in serious infections or cancers, suggesting early treatment may change the course of the disease.

Topics Biologics and newer medicines Research

Jargon explained top-down step-up disease modification stricturing penetrating disease

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease (FORTIFY)

The Lancet Study May 2022 For professionals

The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.

Topics Biologics and newer medicines Research

Jargon explained IL-23 maintenance placebo endoscopic response

Case reports 1

Pyoderma Gangrenosum in a Patient with Crohn's Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature

Clinical Practice Case report Mar 2025 For professionals

Describes a 23-year-old woman with Crohn's who developed pyoderma gangrenosum and improved on adalimumab, alongside a review of similar published cases. The authors stress early diagnosis and joint care between specialists.

Topics Beyond the gut Biologics and newer medicines

Jargon explained pyoderma gangrenosum adalimumab